Keywords: USA, FDA, Johnson & Johnson Fulranumab, Regeneron,, Sanofi-Aventis, Abbott Labs, REGN475, Pfizer, AstraZeneca

USA’s FDA puts stops on Johnson & Johnson’s fulranumab and Regeneron/Sanofi-Aventis osteo drug due to side effect risks

Article | 04 January 2011

Print This

US health care giant Johnson & Johnson (NYSE: JNJ) has halted studies of experimental painkillers due to concerns that a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in